{
    "organizations": [],
    "uuid": "fd7e3a667bf8cb66a372a0e879ab842c7145ccc9",
    "author": "",
    "url": "https://www.reuters.com/article/brief-summit-completes-dosing-of-ezutrom/brief-summit-completes-dosing-of-ezutromid-in-phaseout-dmd-clinical-trial-idUSASC09WG9",
    "ord_in_thread": 0,
    "title": "BRIEF-Summit Completes Dosing Of Ezutromid In Phaseout Dmd Clinical Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " Summit Completes Dosing Of Ezutromid In Phaseout Dmd Clinical Trial Reuters Staff \n  Summit Therapeutics PLC: \n* SUMMIT COMPLETES DOSING OF EZUTROMID IN PHASEOUT DMD CLINICAL TRIAL \n* SUMMIT THERAPEUTICS PLC - TOP-LINE DATA FROM FULL TRIAL CONTINUE TO BE EXPECTED IN Q3 2018   (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-19T14:18:00.000+03:00",
    "crawled": "2018-04-19T14:38:20.056+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "summit",
        "completes",
        "dosing",
        "ezutromid",
        "phaseout",
        "dmd",
        "clinical",
        "trial",
        "reuters",
        "staff",
        "summit",
        "therapeutic",
        "plc",
        "summit",
        "completes",
        "dosing",
        "ezutromid",
        "phaseout",
        "dmd",
        "clinical",
        "trial",
        "summit",
        "therapeutic",
        "plc",
        "data",
        "full",
        "trial",
        "continue",
        "expected",
        "q3"
    ]
}